利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.028 秒)

    Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
    1.
    发明授权
    Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof 有权

    公开(公告)号：US11897927B2

    公开(公告)日：2024-02-13

    申请号：US16348274

    申请日：2017-11-30

    申请人： Advaxis, Inc.

    发明人： Robert Petit ,  Michael F. Princiotta ,  Brandon Coder ,  David Balli

    IPC分类号： C07K14/47 ,  A61K35/74 ,  A61K39/00 ,  C12N15/74

    CPC分类号： C07K14/4748 ,  A61K35/74 ,  A61K39/0011 ,  A61K39/00115 ,  A61K39/001103 ,  A61K39/001104 ,  A61K39/001107 ,  A61K39/001157 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001189 ,  A61K39/001194 ,  A61K39/001195 ,  C12N15/74 ,  A61K2039/523 ,  A61K2039/55544 ,  A61K2039/55594 ,  A61K2039/645 ,  C07K2319/43 ,  C07K2319/95

    摘要： Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

    Immunogenic Compositions Targeting Recurrent Cancer Mutations And Methods Of Use Thereof
    6.
    发明申请
    Immunogenic Compositions Targeting Recurrent Cancer Mutations And Methods Of Use Thereof 审中-公开

    公开(公告)号：US20190322714A1

    公开(公告)日：2019-10-24

    申请号：US16348274

    申请日：2017-11-30

    申请人： Advaxis, Inc.

    发明人： Robert Petit ,  Michael F. Princiotta ,  Brandon Coder ,  David Balli

    IPC分类号： C07K14/47 ,  A61K35/74 ,  A61K39/00 ,  C12N15/74

    摘要： Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-tumor-associated-antigen immune response in a subject, methods of inducing an anti-tumor or anti-cancer immune response in a subject, methods of treating a tumor or cancer in a subject, methods of preventing a tumor or cancer in a subject, and methods of protecting a subject against a tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

    Listeria-Based Immunogenic Compositions Comprising Wilms Tumor Protein Antigens And Methods Of Use Thereof
    8.
    发明申请
    Listeria-Based Immunogenic Compositions Comprising Wilms Tumor Protein Antigens And Methods Of Use Thereof 审中-公开

    公开(公告)号：US20190248856A1

    公开(公告)日：2019-08-15

    申请号：US16315082

    申请日：2017-06-30

    申请人： Advaxis, Inc.

    发明人： Michael Princiotta ,  Robert Petit

    IPC分类号： C07K14/47 ,  C07K14/195 ,  A61K39/39 ,  A61K39/00 ,  A61P35/00

    CPC分类号： C07K14/4748 ,  A61K39/0011 ,  A61K39/001153 ,  A61K39/39 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/572 ,  A61P35/00 ,  C07K14/00 ,  C07K14/195 ,  C07K14/4702 ,  C07K2319/00 ,  C07K2319/02

    摘要： Provided are Listeria-based immunogenic compositions comprising Wilms tumor protein (WT1) antigens and methods for treating and vaccinating against cancer and inducing an immune response against the same in a subject. Also provided herein are recombinant fusion polypeptides or chimeric polypeptides comprising Wilms tumor protein antigens, nucleic acids encoding such chimeric polypeptides or fusion polypeptides, recombinant bacteria or Listeria strains comprising such chimeric polypeptides or fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such chimeric polypeptides or fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such chimeric polypeptides or fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-WT1 immune response in a subject, methods of inducing an anti-WT1-expressing-tumor or anti-WT1-expressing-cancer immune response in a subject, methods of treating a WT1-expressing or WT1-associated tumor or cancer in a subject, methods of preventing a WT1-expressing or WT1-associated tumor or cancer in a subject, and methods of protecting a subject against a WT1-expressing or WT1-associated tumor or cancer using such recombinant chimeric polypeptides or fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

    Biomarker directed multi-target immunotherapy
    9.
    发明授权
    Biomarker directed multi-target immunotherapy 有权

    公开(公告)号：US10143734B2

    公开(公告)日：2018-12-04

    申请号：US15119661

    申请日：2015-02-18

    申请人： Advaxis, Inc.

    发明人： Robert Petit

    IPC分类号： A61K39/02 ,  C12Q1/6886 ,  G01N33/574 ,  A61K45/06 ,  A61K39/00 ,  C07K14/195

    摘要： This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted Listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a. obtaining a biological sample from said subject; b. evaluating the expression of a predetermined number of biomarkers in said biological sample; c. administering to said subject a composition comprising a recombinant Listeria strain, said strain comprising a nucleic acid sequence encoding at least one fusion protein, wherein said fusion protein comprises a biomarker identified in said biological sample, wherein said biomarker is associated with said disease, wherein said biomarker is fused to a PEST-containing polypeptide, and wherein each fusion protein within said Listeria comprises a different biomarker, thereby treating said disease in said subject.